ReCyte Therapeutics
ReCyte Therapeutics is a regenerative-medicine business established in 2007 as Embryome Sciences and renamed in 2010. Its research has included cell reprogramming and vascular and endothelial-cell regeneration. An indirect majority interest transferred to Juvenescence in December 2024 through the acquisition of UniverXome Bioengineering.
Key facts
| Also Known As | ReCyte Therapeutics, Inc. |
|---|---|
| Company Operating Status | Acquired |
| Wellfound ID | recyte-therapeutics |